华海药业获得盐酸纳洛酮注射液药品注册证书

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Group 1: Product Approval - The approval is for Naloxone Hydrochloride Injection, which is indicated for multiple uses including reversing respiratory depression caused by opioid drugs during anesthesia recovery [1] - The product can also be used to partially or completely reverse respiratory depression due to opioid overdose, rescue acute ethanol poisoning, and diagnose acute opioid overdose [1]